IL314212A - Treatment of GM2 gangliosidosis - Google Patents
Treatment of GM2 gangliosidosisInfo
- Publication number
- IL314212A IL314212A IL314212A IL31421224A IL314212A IL 314212 A IL314212 A IL 314212A IL 314212 A IL314212 A IL 314212A IL 31421224 A IL31421224 A IL 31421224A IL 314212 A IL314212 A IL 314212A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- subject
- formula
- crystalline form
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22150783.3A EP4209215A1 (en) | 2022-01-10 | 2022-01-10 | Treatment of gm2 gangliosidosis |
| EP22193136 | 2022-08-31 | ||
| PCT/EP2023/050459 WO2023131720A1 (en) | 2022-01-10 | 2023-01-10 | Treatment of gm2 gangliosidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314212A true IL314212A (en) | 2024-09-01 |
Family
ID=84982296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314212A IL314212A (en) | 2022-01-10 | 2023-01-10 | Treatment of GM2 gangliosidosis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250120958A1 (https=) |
| EP (2) | EP4714497A2 (https=) |
| JP (1) | JP2025501646A (https=) |
| AU (1) | AU2023205441A1 (https=) |
| CA (1) | CA3242701A1 (https=) |
| IL (1) | IL314212A (https=) |
| MX (1) | MX2024008583A (https=) |
| TW (1) | TW202337456A (https=) |
| WO (1) | WO2023131720A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202539666A (zh) * | 2024-02-01 | 2025-10-16 | 荷蘭商雅捷法羅斯公司 | Gm1神經節苷脂儲積症之治療 |
| EP4595964A1 (en) * | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| WO2026013261A1 (en) | 2024-07-11 | 2026-01-15 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
| EP4678174A1 (en) | 2024-07-11 | 2026-01-14 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461812B1 (en) | 2014-03-27 | 2021-10-13 | Academisch Medisch Centrum | N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| EP3978474A1 (en) * | 2020-10-02 | 2022-04-06 | Azafaros B.V. | Crystalline forms of a pharmaceutical compound |
-
2023
- 2023-01-10 EP EP25220465.6A patent/EP4714497A2/en active Pending
- 2023-01-10 MX MX2024008583A patent/MX2024008583A/es unknown
- 2023-01-10 JP JP2024539849A patent/JP2025501646A/ja active Pending
- 2023-01-10 EP EP23700690.3A patent/EP4463157B1/en active Active
- 2023-01-10 IL IL314212A patent/IL314212A/en unknown
- 2023-01-10 US US18/727,631 patent/US20250120958A1/en active Pending
- 2023-01-10 CA CA3242701A patent/CA3242701A1/en active Pending
- 2023-01-10 AU AU2023205441A patent/AU2023205441A1/en active Pending
- 2023-01-10 TW TW112101050A patent/TW202337456A/zh unknown
- 2023-01-10 WO PCT/EP2023/050459 patent/WO2023131720A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023131720A1 (en) | 2023-07-13 |
| TW202337456A (zh) | 2023-10-01 |
| EP4714497A2 (en) | 2026-03-25 |
| US20250120958A1 (en) | 2025-04-17 |
| JP2025501646A (ja) | 2025-01-22 |
| EP4463157A1 (en) | 2024-11-20 |
| CA3242701A1 (en) | 2023-07-13 |
| MX2024008583A (es) | 2024-07-23 |
| EP4463157C0 (en) | 2026-02-25 |
| EP4463157B1 (en) | 2026-02-25 |
| AU2023205441A1 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4463157B1 (en) | Treatment of gm2 gangliosidosis | |
| TWI694069B (zh) | 治療精神分裂症之醫藥調配物 | |
| BRPI0612921A2 (pt) | composições farmacêuticas de um esteróide neuroativo e métodos de uso do mesmo | |
| JP7809655B2 (ja) | 医薬化合物の結晶形態 | |
| EP4243602A1 (en) | Improved use of cannabinoids in the treatment of alzheimer's disease | |
| EP4209215A1 (en) | Treatment of gm2 gangliosidosis | |
| KR20250007527A (ko) | 메셈브린의 염 형태 | |
| US9717718B2 (en) | Anti-inflammatory compounds | |
| CN118632693A (zh) | Gm2神经节苷脂贮积症的治疗 | |
| EP4101448B1 (en) | Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability | |
| EP4053129B1 (en) | Ginkgolide a for use in the treatment of autism | |
| TW202539666A (zh) | Gm1神經節苷脂儲積症之治療 | |
| US20230024384A1 (en) | Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders | |
| EP4595964A1 (en) | Treatment of gm1 gangliosidosis | |
| CN112691102A (zh) | 黄芩素在防治帕金森病/帕金森综合征抑郁症状中的应用 | |
| EP4678174A1 (en) | Nizubaglustat for use in the treatment of lysosomal storage disorders | |
| JP2021524853A (ja) | ハンチントン病を治療するのに使用するための薬学的化合物 | |
| WO2026013261A1 (en) | Nizubaglustat for use in the treatment of lysosomal storage disorders | |
| JP2006290772A (ja) | 多発性硬化症治療剤 | |
| CN117797134A (zh) | 一种4-tmap治疗或缓解抑郁症的用途 |